Total Funding
91
76
Total FundingSeries A raised
Growth Score
-4 pts
Heat Score
-19 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
7742
Immutrin is a biotech developing next‑generation antibody therapies to clear amyloid deposits and reverse amyloidosis.
- Robert Blaustein: Chief Medical OfficerPast Role: Edgewise Therapeutics, Chief Development Officer
- Mihriban Tuna: Chief Executive OfficerPast Role: Adaptate Biotherapeutics, CSO
About the Company
Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively and
specifically remove established amyloid fibrils.
